JAGX — Jaguar Health, Inc.

Summary of JAGX Q2 2025 Earnings Call

1. Key Financial Results and Metrics:

• Combined net revenue for Q2 2025 was approximately $3 million, marking a 35% increase from Q1 2025 ($2.2 million) and a 10% increase from Q2 2024 ($2.7 million).
• Mytesi prescription volume rose by 6.5% compared to Q1 2025, remaining stable compared to Q2 2024.
• Loss from operations increased to $8 million, up from $7.2 million in Q2 2024.
• Non-GAAP recurring EBITDA showed a net loss of $7.9 million, an improvement from a loss of $8.8 million in Q2 2024.
• Net loss attributable to common shareholders increased to $10.4 million from $9.5 million in the prior year.

2. Strategic Updates and Business Highlights:

• The company is focusing on business development partnerships to secure nondilutive funding for its Human and Animal Health products.
• Recent clinical catalysts include promising results from a proof-of-concept study of crofelemer for treating intestinal failure in pediatric patients with MVID and short bowel syndrome, showing significant reductions in TPN requirements.
• Jaguar is conducting two Phase II trials for crofelemer targeting pediatric MVID and adult short bowel syndrome patients, with results expected in H1 2026.
• The company is also pursuing an expanded indication for crofelemer to treat cancer therapy-related diarrhea (CTD), particularly in breast cancer patients, following a successful FDA Type C meeting.

3. Forward Guidance and Outlook:

• Jaguar anticipates that the convergence of clinical and regulatory catalysts will enhance business development opportunities and lead to significant nondilutive funding.
• The company is preparing to submit a protocol for a pivotal treatment trial for crofelemer in metastatic breast cancer patients, aiming for regulatory approval by 2026.
• Continued focus on expanding crofelemer's applications in both human and animal health sectors.

4. Bad News, Challenges, or Points of Concern:

• The increase in operational losses and net loss attributable to shareholders raises concerns about the company's financial sustainability.
• The Phase III trial for crofelemer in cancer patients did not meet its primary endpoint, which could impact future regulatory approvals and market perceptions.
• The need for ongoing business development partnerships may indicate a reliance on external funding sources amidst a challenging investment climate for emerging pharma companies.

5. Notable Q&A Insights:

• Management emphasized the importance of the recent clinical trial results in attracting potential partners and investors.
• There was a discussion on the unique market position of crofelemer, particularly in addressing unmet needs in rare diseases and cancer therapy-related side effects.
• The management acknowledged the competitive pressures in the pharmaceutical industry but expressed confidence in the differentiated nature of their product offerings.

Overall, while Jaguar Health reported positive revenue growth and significant clinical advancements, it faces challenges with increasing losses and the need for strategic partnerships to support its ambitious development plans.